M J Delforterie1, M T Lynskey2, A C Huizink1, H E Creemers3, J D Grant4, L R Few4, A L Glowinski4, D J Statham5, T J Trull6, K K Bucholz4, P A F Madden4, N G Martin7, A C Heath4, A Agrawal8. 1. VU University, Department of Developmental Psychology and EMGO Institute for Health and Care Research, Amsterdam, The Netherlands. 2. Addictions Department, Institute of Psychiatry, King's College London, United Kingdom. 3. Research Institute of Child Development and Education, University of Amsterdam, Amsterdam, The Netherlands. 4. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA. 5. School of Social Sciences, University of the Sunshine Coast, Queensland, Australia. 6. University of Missouri, Department of Psychological Sciences, Columbia, MO, USA. 7. QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. 8. Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: arpana@wustl.edu.
Abstract
BACKGROUND: In the present study, we examined the relationship between cannabis involvement and suicidal ideation (SI), plan and attempt, differentiating the latter into planned and unplanned attempt, taking into account other substance involvement and psychopathology. METHODS: We used two community-based twin samples from the Australian Twin Registry, including 9583 individuals (58.5% female, aged between 27 and 40). The Semi-Structured Assessment of the Genetics of Alcoholism (SSAGA) was used to assess cannabis involvement which was categorized into: (0) no cannabis use (reference category); (1) cannabis use only; (2) 1-2 cannabis use disorder symptoms; (3) 3 or more symptoms. Separate multinomial logistic regression analyses were conducted for SI and suicide attempt with or without a plan. Twin analyses examined the genetic overlap between cannabis involvement and SI. RESULTS: All levels of cannabis involvement were related to SI, regardless of duration (odds ratios [ORs]=1.28-2.00, p<0.01). Cannabis use and endorsing ≥3 symptoms were associated with unplanned (SANP; ORs=1.95 and 2.51 respectively, p<0.05), but not planned suicide attempts (p>0.10). Associations persisted even after controlling for other psychiatric disorders and substance involvement. Overlapping genetic (rG=0.45) and environmental (rE=0.21) factors were responsible for the covariance between cannabis involvement and SI. CONCLUSIONS: Cannabis involvement is associated, albeit modestly, with SI and unplanned suicide attempts. Such attempts are difficult to prevent and their association with cannabis use and cannabis use disorder symptoms requires further study, including in different samples and with additional attention to confounders.
BACKGROUND: In the present study, we examined the relationship between cannabis involvement and suicidal ideation (SI), plan and attempt, differentiating the latter into planned and unplanned attempt, taking into account other substance involvement and psychopathology. METHODS: We used two community-based twin samples from the Australian Twin Registry, including 9583 individuals (58.5% female, aged between 27 and 40). The Semi-Structured Assessment of the Genetics of Alcoholism (SSAGA) was used to assess cannabis involvement which was categorized into: (0) no cannabis use (reference category); (1) cannabis use only; (2) 1-2 cannabis use disorder symptoms; (3) 3 or more symptoms. Separate multinomial logistic regression analyses were conducted for SI and suicide attempt with or without a plan. Twin analyses examined the genetic overlap between cannabis involvement and SI. RESULTS: All levels of cannabis involvement were related to SI, regardless of duration (odds ratios [ORs]=1.28-2.00, p<0.01). Cannabis use and endorsing ≥3 symptoms were associated with unplanned (SANP; ORs=1.95 and 2.51 respectively, p<0.05), but not planned suicide attempts (p>0.10). Associations persisted even after controlling for other psychiatric disorders and substance involvement. Overlapping genetic (rG=0.45) and environmental (rE=0.21) factors were responsible for the covariance between cannabis involvement and SI. CONCLUSIONS: Cannabis involvement is associated, albeit modestly, with SI and unplanned suicide attempts. Such attempts are difficult to prevent and their association with cannabis use and cannabis use disorder symptoms requires further study, including in different samples and with additional attention to confounders.
Authors: Elliot C Nelson; Andrew C Heath; Pamela A F Madden; M Lynne Cooper; Stephen H Dinwiddie; Kathleen K Bucholz; Anne Glowinski; Tara McLaughlin; Michael P Dunne; Dixie J Statham; Nicholas G Martin Journal: Arch Gen Psychiatry Date: 2002-02
Authors: M T Lynskey; A C Heath; E C Nelson; K K Bucholz; P A F Madden; W S Slutske; D J Statham; N G Martin Journal: Psychol Med Date: 2002-02 Impact factor: 7.723
Authors: Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis Journal: Lancet Date: 2007-07-28 Impact factor: 79.321
Authors: Lauren R Few; Julia D Grant; Elliot C Nelson; Timothy J Trull; Richard A Grucza; Kathleen K Bucholz; Karin J H Verweij; Nicholas G Martin; Dixie J Statham; Pamela A F Madden; Andrew C Heath; Michael T Lynskey; Arpana Agrawal Journal: J Stud Alcohol Drugs Date: 2016-11 Impact factor: 2.582
Authors: Arpana Agrawal; Rebecca Tillman; Richard A Grucza; Elliot C Nelson; Vivia V McCutcheon; Lauren Few; Kenneth R Conner; Michael T Lynskey; Danielle M Dick; Howard J Edenberg; Victor M Hesselbrock; John R Kramer; Samuel Kuperman; John I Nurnberger; Marc A Schuckit; Bernice Porjesz; Kathleen K Bucholz Journal: J Affect Disord Date: 2017-02-03 Impact factor: 4.839
Authors: Lauren R Few; Kimberly B Werner; Carolyn E Sartor; Julia D Grant; Timothy J Trull; Matthew K Nock; Kathleen K Bucholz; Sarah K Deitz; Anne L Glowinski; Nicholas G Martin; Elliot C Nelson; Dixie J Statham; Pamela A F Madden; Andrew C Heath; Michael T Lynskey; Arpana Agrawal Journal: Alcohol Clin Exp Res Date: 2015-10-14 Impact factor: 3.455
Authors: A Waterreus; P Di Prinzio; J C Badcock; M Martin-Iverson; A Jablensky; V A Morgan Journal: Psychopharmacology (Berl) Date: 2018-05-16 Impact factor: 4.530